奥贝法齐莫对接受抑制性抗逆转录病毒治疗的人免疫缺陷病毒感染者病毒持续、炎症和免疫激活的影响
研究评估奥贝法齐莫在24例ART抑制的HIV感染者(50mg每日12周13例或150mg每日4周11例)及12例HIV阴性者(50mg每日4周)中的安全性及对HIV-1持续、免疫激活和炎症的影响。50mg和150mg剂量均安全,150mg耐受性较差;150mg降低HIV-1 DNA(P=.008,中位倍数变化=0.6)和基线可检测病毒血症者的残余病毒血症,并上调miR-124、降低激活标志物和炎症生物标志物。作者认为其减少慢性免疫激活和炎症的作用提示可能在涉及免疫激活化合物的病毒缓解策略中发挥作用。
要点
- 50mg和150mg奥贝法齐莫均安全,但150mg剂量耐受性较差。
- 150mg剂量降低HIV-1 DNA(P=.008,中位倍数变化=0.6)及基线可检测病毒血症者的残余病毒血症。
- 奥贝法齐莫上调所有参与者的miR-124,降低CD38、HLA-DR、PD-1及多种炎症生物标志物。
核心结论
- 奥贝法齐莫减少慢性免疫激活和炎症的作用提示其可能在涉及其他免疫激活化合物(如潜伏逆转剂)的病毒缓解策略中具有潜在作用。
研究设计与样本
- 研究比较了24例ART抑制的HIV感染者接受奥贝法齐莫50mg每日12周(n=13)或150mg每日4周(n=11),以及12例HIV阴性者接受50mg每日4周。
- 评估内容包括奥贝法齐莫相关不良事件、细胞相关HIV-1 DNA和RNA变化、残余病毒血症、免疫表型及血液和直肠组织炎症生物标志物。
主要发现
- 50mg和150mg剂量奥贝法齐莫均安全,但150mg剂量耐受性较差。
- 150mg剂量降低HIV-1 DNA(P=.008,中位倍数变化=0.6)。
- 150mg剂量降低所有基线可检测病毒血症者的残余病毒血症。
- 奥贝法齐莫上调所有参与者的miR-124,并降低激活标志物CD38、HLA-DR、PD-1及多种炎症生物标志物。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Persistence of viral reservoirs has been observed in people with human immunodeficiency virus (HIV), despite long-term antiretroviral therapy (ART), and likely contributes to chronic immune activation and inflammation. Obefazimod is a novel drug that inhibits human immunodeficiency virus type 1 (HIV-1) replication and reduces inflammation. Here we assess whether obefazimod is safe and might impact HIV-1 persistence, chronic immune activation, and inflammation in ART-suppressed people with HIV. METHODS: We evaluated obefazimod-related adverse events, changes in cell-associated HIV-1 DNA and RNA, residual viremia, immunophenotype, and inflammation biomarkers in blood and rectal tissue. We compared 24 ART-suppressed people with HIV who received daily doses of 50 mg obefazimod for 12 weeks (n = 13) or 150 mg for 4 weeks (n = 11) and 12 HIV-negative individuals who received 50 mg for 4 weeks. RESULTS: The 50- and 150-mg doses of obefazimod were safe, although the 150-mg dose showed inferior tolerability. The 150-mg dose reduced HIV-1 DNA (P = .008, median fold change = 0.6) and residual viremia in all individuals with detectable viremia at baseline. Furthermore, obefazimod upregulated miR-124 in all participants and reduced the activation markers CD38, HLA-DR, and PD-1 and several inflammation biomarkers. CONCLUSIONS: The effect of obefazimod by reducing chronic immune activation and inflammation suggests a potential role for the drug in virus remission strategies involving other compounds that can activate immune cells, such as latency-reversing agents.
引用
- Bernal S, Puertas MC, Morón-López S, et al. Impact of Obefazimod on Viral Persistence, Inflammation, and Immune Activation in People With Human Immunodeficiency Virus on Suppressive Antiretroviral Therapy. J Infect Dis. 2023. PMID: 37395474. doi:10.1093/infdis/jiad251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。